The reduced soluble fibrinogen-like protein 2 and regulatory T cells in acute coronary syndrome. Issue 4 (February 2016)

• Record Type: Journal Article
• Authors: Liu, Kun; Li, Ting; Huang, Shiyuan; Long, Rui; You, Ya; Liu, Jinping; Wang, Zhaohui
• Is Part Of: Experimental biology and medicine. Volume 241:Issue 4(2016)
• Page Start: 421
• Page End: 425
• Publication Date: 2016-02
• Subjects: Soluble fibrinogen-like protein 2 -- regulatory T cells -- atherosclerosis; Physiology -- Periodicals; Biology, Experimental -- Periodicals; Medicine, Experimental -- Periodicals; 610.72
• DOI: 10.1177/1535370215612138
• Languages: English
• ISSNs: 1535-3702

Abstract

Soluble fibrinogen-like protein 2, sfgl2, is the new effector of CD4 + CD25 + FOXP3 + regulatory T cell (Treg) and exerts immunosuppressive activity. We design this study to investigate the possible role of sfgl2 in atherosclerosis. A total of 58 acute coronary syndrome (ACS) patients, together with 22 stable angina (SA) patients and 31 normal coronary artery (NCA) people were enrolled in our study. Serum level of sfgl2 and plasma level of Treg were respectively measured. In line with the change of Treg, serum level of sfgl2 in ACS (8.70 ng/mL) was significantly decreased ( P = 0.003), compared with that in SA (11.86 ng/mL) and NCA (17.55 ng/mL). Both sfgl2 and Treg level were obviously decreased in ACS; Sfgl2 may play a protective role in atherosclerosis.